GlassScriptPhysician profile
Omar Al Ustwani
NPI 1275769978
$7,415.17
in general payments reported to CMS, 2019-2025
69 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $238 · 2021: $315 · 2022: $1,091 · 2023: $1,432 · 2024: $1,261 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,059.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $676.24 | 2019-2025 | |
| Pfizer INC. | $519.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $405.03 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $395.67 | 2019-2025 | Lynparza, Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $392.94 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Genentech USA, INC. | $355.88 | 2019-2025 | Tecentriq, Phesgo, Perjeta |
| Glaxosmithkline, LLC. | $276.00 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $241.85 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $218.30 | 2020-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $192.06 | 2022-2025 | Reblozyl, Opdualag |
| Janssen Biotech, INC. | $190.94 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Astellas Pharma US INC | $183.36 | 2022-2025 | Padcev, Xospata |
| Kite Pharma, INC. | $173.79 | 2019-2025 | Yescarta |
| Abbvie INC. | $165.47 | 2022-2025 | Venclexta |
| Genzyme Corporation | $156.74 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $149.89 | 2019-2024 | Xarelto |
| Eisai INC. | $148.71 | 2022-2025 | |
| Abbott Laboratories | $147.11 | 2019 | |
| Exelixis INC. | $146.75 | 2019-2025 | Cabometyx |
| Array Biopharma INC | $143.04 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $122.04 | 2022-2023 | Padcev, Adcetris |
| Incyte Corporation | $113.04 | 2020-2025 | Jakafi, Zynyz, Monjuvi |
| Gilead Sciences, INC. | $106.00 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $90.45 | 2021-2025 | Tevimbra, Brukinsa |
| Sobi, INC | $88.50 | 2024-2025 | |
| Lilly USA, LLC | $85.06 | 2019-2025 | Verzenio |
| Tempus Ai, INC | $68.70 | 2024-2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $67.59 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $64.58 | 2024 | Clonoseq |
| Invivyd INC | $61.36 | 2025 | Pemgarda |
| Emd Serono, INC. | $60.48 | 2022-2024 | Tepmetko |
| Springworks Therapeutics, INC. | $59.25 | 2025 | Ogsiveo, Gomekli |
| Genmab U.S., INC. | $59.09 | 2022-2025 | Tivdak, Epkinly |
| Pharmacosmos Therapeutics INC. | $55.64 | 2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $53.92 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.86 | 2022-2025 | |
| Stemline Therapeutics INC. | $50.17 | 2023-2024 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $49.92 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $49.02 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $46.62 | 2019-2023 | Ninlaro |
| Amgen INC. | $46.57 | 2022-2023 | Nplate, Xgeva, Kyprolis |
| Tersera Therapeutics LLC | $46.51 | 2019-2024 | Xermelo |
| Organon LLC | $38.63 | 2021-2022 | |
| Beone Medicines USA, INC. | $34.90 | 2025 | Tevimbra, Brukinsa |
| Puma Biotechnology, INC. | $34.71 | 2024-2025 | |
| Geron Corporation | $32.81 | 2024-2025 | Rytelo |
| Acrotech Biopharma INC. | $31.96 | 2022-2025 | Ryzneuta |
| Amneal Pharmaceuticals LLC | $31.26 | 2025 | Alymsys |
| Helsinn Therapeutics (U.S.), INC. | $30.94 | 2021-2025 | Akynzeo |
| Deciphera Pharmaceuticals INC. | $30.84 | 2022-2024 | Qinlock |
| Kyowa Kirin, INC. | $30.00 | 2019 | |
| Celltrion USA INC. | $27.97 | 2024-2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $27.67 | 2022-2025 | |
| Secura Bio, INC. | $27.07 | 2023 | Copiktra |
| Amag Pharmaceuticals, INC. | $26.66 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $25.70 | 2020 | |
| Novocure INC. | $20.78 | 2025 | Optune Lua (Novottf-200t) |
| Octapharma USA, INC. | $19.03 | 2019 | |
| Servier Pharmaceuticals LLC | $18.92 | 2025 | |
| Agios Pharmaceuticals, INC. | $18.86 | 2024 | Pyrukynd |
| Cti Biopharma Corp. | $17.38 | 2022 | |
| Immunocore Limited | $16.83 | 2025 | Kimmtrak |
| Mirati Therapeutics, INC. | $15.49 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $14.84 | 2023 | Empaveli |
| Morphosys, US INC. | $14.76 | 2021 | |
| Shield Therapeutics INC | $14.43 | 2025 | |
| Sumitomo Pharma America, INC. | $13.50 | 2025 | Orgovyx |
| Advanced Accelerator Applications | $12.85 | 2020 | |
| Clovis Oncology, INC. | $10.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Al Ustwani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.